RESEARCH TRIANGLE PARK, N.C., Jan. 7 /PRNewswire/ --
Paradigm Genetics, Inc. (Nasdaq: PDGM) today announced that John A. Ryals,
Ph.D., CEO and President, will speak at the JPMorgan H&Q Annual Healthcare
Conference Monday, January 7. His presentation will review Paradigm's
application of its proprietary metabolomics technology platform to drug
discovery and development.
DATE: Monday, January 7, 2002
TIME: 10:00 a.m. Pacific Standard Time
A link to the archived webcast of Dr. Ryals' presentation may be found at
http://www.paradigmgenetics.com or http://www.eventsdigital.com/events/jpmhq/healthcare2002
About Paradigm Genetics
Paradigm Genetics, Inc. (Nasdaq: PDGM), headquartered in Research Triangle
Park, NC, is an integrated life sciences company developing novel technologies
to speed the discovery of products for the advancement of human health,
agriculture and nutrition. In human health, Paradigm seeks to use its
proprietary MetaVantage(TM) metabolomics technology platform to transform drug
discovery and development by significantly enhancing the study of drug
targets, lead compounds, and predictive medicine. MetaVantage(TM) elucidates
the metabolic profile of a cell, tissue, or fluid, and integrates this
information with data from other genomics analyses using its proprietary
comprehensive informatics system. By globally interrogating biochemistry, the
MetaVantage(TM) technology extends traditional genomic technologies to reveal
the next level of cellular information. For more information, visit
http://www.paradigmgenetics.com.
This press release contains forward-looking statements, including
statements regarding Paradigm's ability to develop novel technologies to speed
the discovery of products for the advancement of human health, agriculture and
nutrition; and Paradigm's ability to use its metabolomics technology platform
to transform drug discovery and development by significantly enhancing the
study of drug targets, lead compounds, and predictive medicine. Such forward-
looking statements are based on management's current expectations and are
subject to a number of risks, factors and uncertainties that may cause actual
results, events and performance to differ materially from those referred to in
the forward-looking statements. These risks include, but are not limited to,
Paradigm's early stage of development, history of net losses, technological
and product development uncertainties, reliance on research collaborations,
uncertainty of additional funding and ability to protect its patents and
proprietary rights. These and other risks are identified in Paradigm's report
on 10-Q for the quarter ended September 30, 2001, filed with the Securities
and Exchange Commission.
MetaVantage(TM) and MetaTrace(TM) are U.S. trademarks of Paradigm
Genetics, Inc.
SOURCE Paradigm Genetics, Inc.
 back to top
Related links:
http://www.paradigmgenetics.com
Audio:http://www.eventsdigital.com/events/jpmhq/healthcare2002
CONTACT:
Melissa Matson, Manager, Corporate
Communications of Paradigm Genetics, Inc., +1-919-425-3000, or
Lydia Sanmarti-Vila, Ph.D., Senior Account Executive of
Noonan-Russo Communications, Inc., +1-212-696-4455 ext. 226, for
Paradigm Genetics, Inc.
|
